immunotherapy Archives - Express Pharma

Shorter immunotherapy duration for advanced melanoma shows comparable disease control in UK DANTE trial

Blood cancers dominate CAR-T pipeline: GlobalData

Mankind Pharma and Innovent Biologics partner to license and commercialise Sintilimab

Bladder cancer diagnosed incident cases across 8MM to reach 0.34 mn in 2033

Merck’s colorectal cancer therapy fails late-stage trial

AstraZeneca shares data from HIMALAYA, MATTERHORN Phase III studies at ESMO Asia Congress 2023

DCGI approves KEYTRUDA to treat triple negative breast cancer, renal cell carcinoma

Israeli researchers develop bio-sensing technology to predict cancer treatment response

Biliary tract cancer drug Durvalumab approval key opportunity for AstraZeneca in India: GlobalData

NIH study advances personalised immunotherapy for metastatic breast cancer